EnamineStore Blog

Lofexidine Retrosynthesis

Lofexidine (Lucemyra®, US Woldmeds LLC) is a medication historically used to treat high blood pressure which was approved by FDA as a first non-opioid drug for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults on May 16, 2018. Lucemyra is not a treatment for opioid use disorder (OUD), but can be used as part of a broader, long-term treatment plan for managing OUD.

Synthesis of this small molecule may be realized starting from these Building Blocks:

Glasdegib retrosynthesis

 

Here are some analogs and similar Building Blocks, available from stock:

(2,6-dichlorophenyl)boronic acid (2,6-dichloro-4-fluorophenyl)boronic acid 4,4,5,5-tetramethyl-2-(2,4,6-trichlorophenyl)-1,3,2-dioxaborolane (2,3,6-trichlorophenyl)boronic acid 2,6-Dichlorobenzenethiol 2,6-dichlorophenol 2-bromo-4,6-dichlorophenol 4-bromo-2,6-dichlorophenol 2-bromo-1,3-dichlorobenzene 2-bromo-1,3-dichloro-5-fluorobenzene 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene 2-chloro-4-(trifluoromethyl)phenol2-chlorohexanenitrile 2-hydroxybutanimidamide hydrochloride 2-chloropropanimidamide hydrochloride (2R)-2-hydroxypropanimidamide hydrochloride 2-bromo-2-cyclopropylacetonitrile 2-chloro-3-methylbutanenitrile 2-chlorobutanenitrile 2-chloropropionitrile 2-bromopropionitrile 2-bromobutanenitrile 2-bromo-3-methylbutanenitrile 1-bromocyclobutane-1-carbonitrile methyl 2-chloropropanoate 2-bromopropanoic acid methyl 2-bromopropionate 1-bromocyclopropane-1-carbonitrile